PR release

Veteran Healthcare Executive Brings Decades of Experience in Clinical Documentation Integrity and Revenue Cycle Transformation

Latin American collection network and banked specimens support broader patient representation and earlier-stage cancer research

Financing follows peer-reviewed NeuroPulse pilot study results and supports a pivotal trial of Rhyvive™, an investigational adjunctive therapy designed to extend AF treatment beyond the hospital and into the home.

Financing follows peer-reviewed NeuroPulse pilot study results and supports a pivotal trial of Rhyvive™, an investigational adjunctive therapy designed to extend AF treatment beyond the hospital and into the home.

First and Only Liquid Embolic Approved for Both Peripheral Arterial Bleeds and Hypervascular Tumors Supported by Two Prospective, Multicenter Pivotal Clinical Trials

Dr. Jason Patterson completed three procedures using Stryker's newest patient-specific ankle technology

Milestone procedures on both coasts mark the arrival of porous titanium on Providence's Level 1 evidence-backed CORUS platform

FDA authorization enables clinical investigation of a fundamentally different approach for patients with early symptomatic Alzheimer's disease

Three new distributor agreements build on initial China sales and extend the Company's distributor-led commercial strategy

Featured symposium will reveal a new vision for intelligent systems that support surgeon judgment, reduce procedural burden and connect the episode of care

The new pathway explores what it will take to build sustainable cataract care and calls for partnership across the global eye-health community

PRINCETON, N.J. , Oct. 29, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results and recent business highlights after the market close on Thursday, November 12, 2026.

Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance

New grant funding supports pelvic health education, treatment assistance and awareness of Medicare and Medicaid coverage for women facing financial barriers.

LINKÖPING, Sweden , October 29, 2026 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Meritus Health has gone live with Sectra's enterprise imaging solution as a cloud service, Sectra One Cloud, initially utilizing the module for radiology. The solution enables radiologists to work in a single application throughout the whole workflow, supporting faster diagnostics for the patients and communities Meritus Health serves.

SHANGHAI , Oct. 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, reported revenue of RMB 10.58 billion for the first nine months of 2026, up 19.43% year-on-year. Sustained investment in innovation supported the company's international expansion, with overseas revenue increasing 50.30% year-on-year to RMB 3.00 billion.

SHANGHAI , Oct. 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, announced its financial results for the first nine months of 2026, reporting revenue of RMB 10.58 billion, up 19.43% year-on-year. In the third quarter, revenue reached RMB 3.53 billion, while net profit attributable to shareholders rose 13% year-on-year to RMB 138 million.

SINGAPORE , Oct. 29, 2026 /PRNewswire/ -- Singapore General Hospital (SGH) has won the Silver Award in the Dr Prathap C Reddy Excellence Award for Clinical Quality and Patient Safety at the International Hospital Federation (IHF) Awards 2026, for its Augmented Intelligence in Infectious Diseases (AI 2 D). It is an artificial intelligence (AI) tool that helps doctors determine whether patients need antibiotics.

TOKYO , Oct. 29, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million 1 ) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NTDs) and emerging & re-emerging infectious diseases such as Ebola disease. 2

SOMERSET, N.J., Oct. 28, 2026 /PRNewswire/ -- Most people know to encourage the women in their lives to stay current with breast cancer screening. But when a friend, partner, mother or colleague is diagnosed, a different question often follows: What treatment options should she ask about?